AD/PD 2025
Apr 1 - 5, 2025 | Vienna, Austria
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Presentation
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy VolunteersL Smits et al.